INTRODUCTION {#s1}
============

Whole-exome sequencing (WES) has become a commonly used tool for both gene discovery in the research setting and accelerated diagnostics in the clinical setting. Reports from ever-increasing patient cohorts have indicated that WES can deliver a molecular diagnosis ∼25% of the time ([@OzanturkMCS000703C30]; [@OzanturkMCS000703C4]). In parallel, the combinatorial application of oligo-based comparative genomic hybridization arrays and computational analyses that infer chromosomal losses/gains from nonuniform read depth have also highlighted an important contribution of copy-number variants (CNVs) to rare genetic disorders ([@OzanturkMCS000703C29]; [@OzanturkMCS000703C28]; [@OzanturkMCS000703C27]).

Despite these advances, a significant fraction of patients tested by these methods yields no overt candidates, even in cases in which the inheritance of the phenotype within a family suggests a strong underlying genetic component. There are many reasons for this, including the persistent difficulties in interpreting rare variation, the low quality or coverage of some regions of the genome, the poor detection of some CNVs, and the contribution of mutations in noncoding regulatory elements. In addition, examples have emerged in which a single-gene--single-syndrome paradigm is not sufficient to explain the inheritance of clinical phenotypes. In some cases, the clinical presentation represents two overlapping disorders, thus confusing locus assignment ([@OzanturkMCS000703C24]; [@OzanturkMCS000703C26]; [@OzanturkMCS000703C30]). In other cases, alleles can interact with each other at discrete loci to modulate penetrance and/or expressivity. These can represent genetic interactions of either single-nucleotide variants (SNVs) ([@OzanturkMCS000703C10]), SNVs with CNVs ([@OzanturkMCS000703C20]; [@OzanturkMCS000703C22]), or, in principle, CNVs with CNVs ([@OzanturkMCS000703C12]).

Here, we report the combinatorial results of quad-based WES and molecular cytogenetic analysis of Turkish male siblings with a constellation of neurocognitive, craniofacial, and gonadal malformations that do not conform readily to an established syndrome or known molecular lesion. The aggregate analysis for SNVs and CNVs identified two dosage perturbations in both affected individuals---a terminal duplication on Chromosome 16q and a terminal deletion on Chromosome 5p---as well as a maternally inherited missense variant (p.Ser105Pro) in *CXorf36*. Functional studies in zebrafish embryos indicated that perturbation of *CXorf36* is unlikely to contribute to the patients' dysmorphic features or cause neurodevelopmental abnormalities, whereas molecular cytogenetic analysis indicated that no gene was disrupted in either CNV boundary. In contrast, retrospective analysis of reported cases led to the identification of a family of Saudi Arabian descent who shared clinical features with our patients and had likewise overlapping 5p loss and 16q gain ([@OzanturkMCS000703C14]). Some clinical features can potentially be explained by dosage defects on either chromosomal location. However, the remaining defects in our patients, which are shared by the previously published family, argue that concomitant haploinsufficiency on 5p and increased gene dosage across 16q constitute the most parsimonious driver hypothesis for this syndrome.

RESULTS {#s2}
=======

Clinical Characterization of a Syndromic Disorder in a Turkish Pedigree {#s2a}
-----------------------------------------------------------------------

We consulted for a nonconsanguineous Turkish family with two male siblings with the primary features of motor delay accompanied by intellectual disability and ambiguous genitalia ([Table 1](#OzanturkMCS000703TB1){ref-type="table"}; [Fig. 1](#OzanturkMCS000703F1){ref-type="fig"}A) at Hacettepe University Hospital. The parents reported no family history of inherited disease, except for a deceased female child who was affected with hypotonia of unknown etiology. We evaluated the oldest affected child (M-11-1496) when he was 11 yr, 4 mo old. Physical examination showed a weight of 26.5 kg (\<5th percentile), height of 124 cm (\<5th percentile), and head circumference of 51 cm. He had a weak cry (cat-like), stridor, and hypotonia at birth; his stridor recovered when he was 18 mo of age. He had delayed developmental milestones: He was able to hold his head up and sit by himself at 4 yr and he walked at 9.5 yr. First, we noted focal neurological deficits and stereotypic movements. He did not respond to his name nor make eye contact, and he was unable to speak. His gait is wide because of pes planus, and he displayed minimal coordination. Second, he has a micropenis, hypospadias, and undescended testes. Moreover, we noted distinct craniofacial and skeletal abnormalities. He had mild scaphocephaly and a distinct facial gestalt, with an elongated face, prominent forehead with a narrow diameter, high arched palate, and low-set ears (the family declined the use of photographs). Additionally, his shoulders are narrow; he has clubbing, thenar and hypothenar types of neural atrophy of his hands, swelling around the interphalangeal joints, and distal atrophy in his lower extremities. Multiple clinical laboratory tests were normal, including blood chemistry, lipid profile, creatinine kinase, routine urine tests, amino acid profile, and biotinidase activity. A hearing test and electromyography were both normal.

![Rare single-nucleotide variants (SNVs) and copy-number variants (CNVs) detected in a Turkish pedigree with a syndrome of unknown etiology. (*A*) Pedigree and genotypes of a nonconsanguineous Turkish family with two affected male siblings. A daughter was presumed to have a different congenital disorder; she had hypotonia and was deceased at 8 mo of age. (*B*) CoNIFER plots, divided into three genomic segments, indicating a breakpoint at position 76,857,179, and a Cytoscan array image (breakpoint at position 76,935,310) are representative of the terminal duplication on Chr 16. (*C*) CoNIFER plots, divided into three genomic segments, indicating a breakpoint at position 7,900,172, and a Cytoscan array image (breakpoint is 8,180,513) are representative of the terminal deletion on Chr 5. Images are from M-11-1497 (see Supplemental Fig. S3 for M-11-1496). Note that the (normal) parental samples are included in the aggregate CoNIFER plots.](OzanturkMCS000703_F1){#OzanturkMCS000703F1}

###### 

Phenotypic comparison between individuals with 16q23 dup and 5p15 del

  --------------------------------------------------------------------------------------
  Phenotype                          Present report   [@OzanturkMCS000703C14]       
  --------------------------------- ---------------- ------------------------- ---- ----
  **Hypotonia**\                           \+                   \+              \+   \+
  ***HP:0001319***                                                                  

  Congenital heart disease\                −                     −              \+   \+
  *HP:0001635*                                                                      

  Umbilical hernia\                        −                     −              \+   \+
  *HP:0001537*                                                                      

  Pectus excavatum\                        −                     −              \+   \+
  *HP:0000767*                                                                      

  **Genital hypoplasia**\                  \+                   \+              \+   \+
  ***HP:0003241***                                                                  

  **Short stature**\                       \+                   \+              \+   \+
  ***HP:0004322***                                                                  

  Hip rotation\                            −                     −              \+   \+
  *HP:0001374*                                                                      

  Metatarsus adductus\                     −                     −              \+   \+
  *HP:0001840*                                                                      

  Clinodactyly\                            −                     −              \+   \+
  *HP:0030084*                                                                      

  **Motor developmental delay**\           \+                   \+              \+   \+
  ***HP:0001270***                                                                  

  **Intellectual disability**\             \+                   \+              \+   \+
  ***HP:0001249***                                                                  

  Brachycephaly\                           −                     −              \+   \+
  *HP:0000248*                                                                      

  **Prominent forehead**\                  \+                   \+              \+   \+
  ***HP:0011220***                                                                  

  **Broad nasal bridge**\                  \+                   \+              \+   \+
  ***HP:0000431***                                                                  

  **Low-set ears**\                        \+                   \+              \+   \+
  ***HP:0000369***                                                                  

  **Arched palate**\                       \+                   \+              \+   \+
  ***HP:0000218***                                                                  

  **Thin upper lip**\                      \+                   \+              \+   \+
  ***HP:0000177***                                                                  

  Esotropia\                               NR                   NR              \+   \+
  *HP:0000565*                                                                      

  **Speech delay**\                        \+                   \+              \+   \+
  ***HP:0000750***                                                                  

  Stridor\                                 \+                   \+              NR   NR
  *HP:0010307*                                                                      

  Scaphocephaly\                           \+                   \+              NR   NR
  *HP:0000268*                                                                      

  Stereotypic movements\                   \+                   \+              NR   NR
  *HP:000733*                                                                       

  Cat-like cry\                            \+                    −              −    −
  *HP:0200046*                                                                      

  Clubbing\                                \+                   \+              NR   NR
  *HP:0001217*                                                                      

  Swollen interphalangeal joints\          \+                   \+              NR   NR
  *HP:0006253*                                                                      

  Distal lower limb amyotrophy\            \+                   \+              NR   NR
  *HP:0008944*                                                                      

  **Narrow shoulders**\                    \+                   \+              \+   \+
  ***HP:0000774***                                                                  

  Pes planus\                              \+                   \+              NR   NR
  *HP:0001763*                                                                      
  --------------------------------------------------------------------------------------

Human Phenotype Ontology (HPO) terms are shown in italics. Phenotypes in bold are common features between presented patients and reported patients in [@OzanturkMCS000703C14].

+, present; −, absent; NR, not recorded.

We observed multiple overlapping phenotypes between M-11-1496 and his younger brother (M-11-1497), who was 8.5 yr old at the time of evaluation. He was born prematurely at 32 wk, he was hypotonic, and his sucking reflex was immature. Additionally, he had stridor that resolved at 12 mo. He was able to hold his head up at 18 mo and walked at 3 yr. A physical examination showed a weight of 19 kg (\<5th percentile), height of 114 cm (\<5th percentile), and head circumference of 50 cm. His neurological findings included motor delay, hypotonia, stereotypic movements, and intellectual disability; he could speak three words after he had speech therapy for 2 yr. He had hypoactive deep tendon reflexes, flexor planar reflexes, and limited eye contact. Also similar to his brother, he displayed genital malformations: He had micropenis, hypospadias, and undescended testes. Further, he had craniofacial and skeletal abnormalities similar to those of his brother. All routine clinical laboratory tests (blood count, lipid profile, amino acid profile, and biotinidase activity) were normal except for mild anemia (hemoglobin \[Hb\], 10.6 g/dL; mean corpuscular volume \[MCV\], 79.6).

WES Reveals a Single X-Linked Candidate {#s2b}
---------------------------------------

To identify the molecular basis of the syndromic features of the affected male siblings, DNA samples from all four individuals in the family were collected; DNA was unavailable from the deceased sister for analysis. The entire quad was subjected to WES, whereas the two patients also underwent clinical aCGH (array comparative genomic hybridization) analysis, with the results of the two studies merged post hoc.

For WES, total coverage for each individual ranged from 92% to 94% of bases covered at 10× (Supplemental Table S1). We first filtered variants against 1000 Genomes, and the 6500 exomes in the EVS (Exome Variant Server), retaining only functional variants present at \<1% minor allele frequency (MAF). Remaining variants were then filtered against the Atherosclerosis Risk in Communities cohort (ARIC; *n* = 2300 exomes) to obtain 468--476 rare variants per individual (Supplemental Table S2). Next, we performed trio analysis for each sibling separately under de novo, autosomal-recessive, or X-linked hypotheses, followed by cross-referencing across siblings to identify genes that shared the same mutations. Individual M-11-1496 had 11 candidate genes and individual M-11-1497 had nine candidate genes (Supplemental Table S3). Among these putative contributing loci, we found a single shared candidate among the two siblings, a missense mutation on the X Chromosome (c.T313C; p.Ser105Pro) in *CXorf36*. Sanger sequencing confirmed that both siblings were hemizygous for this variant, and that they had each inherited the c.T313C change from their carrier mother; the father was hemizygous reference at this position (Supplemental Fig. S1).

Inactivation in Zebrafish Shows That *CXorf36* Is Not the Likely Driver of Pathogenesis {#s2c}
---------------------------------------------------------------------------------------

*CXorf36* encodes a 433-amino-acid putative protein with a predicted molecular weight of 48 kDa. The only implication of this locus in human pathology is a tentative association with autism and X-linked intellectual disability ([@OzanturkMCS000703C2]), whereas the CADD (combined annotation-dependent depletion) score for the discovered allele was 23.8 (and is therefore in the top 1% of likely deleterious mutations \[[@OzanturkMCS000703C16]\]). To test this transcript as our sole candidate derived from SNV analysis of the quad, we turned to the developing zebrafish, a system we have used extensively to test functionally candidate genes and alleles ([@OzanturkMCS000703C25]) for neurodevelopmental defects and facial dysmorphia ([@OzanturkMCS000703C8]; [@OzanturkMCS000703C13]; [@OzanturkMCS000703C9]; [@OzanturkMCS000703C6]). We detected the single ortholog of *CXorf36* in the zebrafish genome (*c9hxorf36*; 48% identity, 89% similarity), and we established that it is expressed during embryonic development by analyzing in-house RNA-seq data from 5 days postfertilization (dpf) heads ([@OzanturkMCS000703C5]). We therefore suppressed *c9hxorf36* using morpholino (MO) antisense oligonucleotides at three different doses (3, 6, and 9 ng). Even at the highest dose, which extinguished ∼90% of endogenous mRNA, we did not observe any differences between morphants and control animals (Supplemental Fig. S2). Testing included analysis of the craniofacial skeleton by Alcian blue staining at 5 dpf, followed by measurements of the angle of ceratohyal cartilage and distance between Meckel\'s cartilage and the ceratohyal cartilage; both yielded measures that were similar between control and MO-injected batches (*n* = 40 embryos/batch; repeated twice; investigator was blind to injection cocktail; [Fig. 2](#OzanturkMCS000703F2){ref-type="fig"}A--C). In addition, calculations of the number of dividing cells in the head (to determine the possible relevance to neurodevelopmental defects) revealed no differences in the numbers and distribution of phospho histone-H3 positive cells at 2 dpf (performed in triplicate; [Fig. 2](#OzanturkMCS000703F2){ref-type="fig"}D,E). Finally, measurement of head size was also similar between MO-injected embryos versus controls (*n* = 35 embryos/batch; triplicated; [Fig. 2](#OzanturkMCS000703F2){ref-type="fig"}F). Similarly, *CXorf36* mRNA overexpression induced no obvious phenotypes. Together, these data suggest that *CXorf36* is unlikely to contribute to the complex clinical presentation of the affected siblings. Consistent with this notion, a recent analysis of exomes in the ExAC (Exome Aggregation Consortium) browser, made available after we had concluded the zebrafish studies, showed that the discovered missense allele, although exceedingly rare in Europeans (five hemizygous males), is present in 91 males of South Asian origin, as well as in two females in homozygosity. In addition, a total of 90 missense and four loss-of-function (LOF) alleles have been reported for this transcript in ExAC, predicting moderate constraint of deleterious alleles for this locus.

![In vivo assessment of *c9hxorf36* suppression in zebrafish. (*A*) Representative ventral images of the craniofacial structure of zebrafish embryos fixed at 5.5 dpf and stained with Alcian blue. (*B*) Quantitative measurement (shown with red lines in *A*) of control and morpholino \[MO\]-injected batches (*n* = 40 embryos/batch; repeated twice) indicate no significant difference in the angle of ceratohyal cartilage in morphants versus controls. (*C*) Quantitative measurement (as indicated with yellow arrows in *A*) of the distance between the ceratohyal and Meckel\'s cartilage resulted in no significant difference between controls and morphant embryos (*n* = 40 embryos/batch; repeated twice). (*D*) Representative lateral images of 2-dpf embryos stained with anti-phospho histone H3 antibody to monitor cell division. (*E*) Quantification of dividing cells in the heads of embryo batches (*n* = 15 embryos/batch); no significant differences were detected. (*F*) Summary of head size measurements as determined by the distance from the most anterior point of Meckel\'s cartilage to the fin attachment on ventral views (as shown in *A*; *n* = 35 embryos/batch); no significant differences were detected. Scale bars (*A*,*D*), 100 µm.](OzanturkMCS000703_F2){#OzanturkMCS000703F2}

CNV Analysis Reveals a 16q Terminal Duplication and a 5p Terminal Deletion {#s2d}
--------------------------------------------------------------------------

Because our functional data did not support the candidacy of *CXorf36* as a driver, we reexamined our exome data seeking other types of lesions. CNV analysis using CoNIFER (COpy Number Inference From Exome Reads; [@OzanturkMCS000703C17]) detected two such lesions: a terminal duplication of Chromosome 16q (16q23.1 → 16qter) and a terminal deletion of Chromosome 5p (15p15.31 → 15pter) proximal to the minimal cri du chat region ([Figs. 1](#OzanturkMCS000703F1){ref-type="fig"}B,C, [3](#OzanturkMCS000703F3){ref-type="fig"}; Supplemental Fig. S3A,B). Both CNVs were present in both affected siblings and were absent from parental exomes, whereas there are no healthy individuals reported in the Database of Genomic Variants (DGV; [http//projects.tcag.ca/variation/](http//projects.tcag.ca/variation/)) with concomitant losses at 5p and gains at 16q. A second CNV algorithm, XHMM (eXome--Hidden Markov Model; [@OzanturkMCS000703C11]), reported the same result (Supplemental Table S4). The presence of two CNVs in both children that were undetectable in either parent hinted at a malsegregation of a parental balanced translocation. We therefore performed karyotype analysis of both affected siblings (the parents refused to provide new parental samples), and we confirmed the presence of a t(5;16) translocation.

![Summary of CNVs on Chromosome 5p and Chromosome 16q from this study and previous reports (nine studies in total). \*, with 2q37 deletion; \*\*, with 5q35.3 deletion; \*\*\*, with 7q22.3 deletion; NR, not recorded. The different reports with CNVs overlapping the 5p and 16q lesions from our study have been assigned a number (1--9, shown in blue). Each row of observed phenotypes indicates the number of individuals with that feature per number evaluated in each report. Phenotypes in bold are both concordant among the individuals with concomitant 5p and 16q CNVs from reports 1 (this study) and 2 ([@OzanturkMCS000703C14]). ^1^Facial dysmorphism includes elongated face with prominent forehead, broad nasal bridge, low ear sets, arched palate, and thin upper lip.](OzanturkMCS000703_F3){#OzanturkMCS000703F3}

To study this genomic lesion further, we cross-referenced our exome data with the molecular cytogenetic analysis performed on both patients on a high-resolution single-nucleotide polymorphism (SNP) array. We confirmed both CNVs and we mapped the breakpoints: The terminal deletion at Chromosome 5 starts at p15.31 (8,180,513) between *MTRR* and *LOC7229506* and encompasses a region containing 40 genes, five pseudogenes, and five microRNA genes; the terminal duplication on Chromosome 16 starts at q23.15 (76,935,310) between *MIR4719* and *MON1B* and contains 110 genes, two pseudogenes, and two microRNA genes ([Figs. 1](#OzanturkMCS000703F1){ref-type="fig"}B,C and [3](#OzanturkMCS000703F3){ref-type="fig"}). Notably, none of the breakpoints disrupted any transcripts, suggesting that the contribution of these CNVs to the complex clinical presentation would have to be driven by dosage imbalance.

The size (13.5 and 7.7 Mb for 16q and 5p, respectively) and large genic content of each CNV precluded systematic functional in vivo testing. As such, the only tractable interpretive tool was retrospective CNV analysis of affected individuals deposited either in the literature or in public databases such as DGV and the Database of Chromosomal Imbalance and Phenotype in Humans (DECIPHER; <https://decipher.sanger.ac.uk>). We found several reports of patients with a CNV overlapping partially with either the 5p deletion or the partial 16q trisomy ([Fig. 3](#OzanturkMCS000703F3){ref-type="fig"}) and a single report of the co-occurrence of the 5p del and 16q dup in one other family ([@OzanturkMCS000703C14]).

Despite the expected phenotypic variability associated with the 16q dup and the 5p del, some phenotypic features can be potentially assigned to dosage imbalance at either chromosomal region. For example, the observed terminal deletion of Chromosome 5p overlaps partially with cri du chat syndrome ([@OzanturkMCS000703C31]), some features of which, such as the cat-like cry speech delay, were recorded in our patient. Similarly, duplications in 16q11 → qter to 16q24 → qter have been reported in patients with features present in our patients, including hypotonia, low-set ears, genital abnormalities, and craniofacial features ([@OzanturkMCS000703C18]). Importantly, a kindred of Saudi Arabian descent with two affected half-brothers was shown to harbor cytogenetic changes and clinical features that overlapped with those in our family: a 1-Mb 5p terminal deletion and a 6-Mb 16q terminal duplication. These two affected siblings bore striking similarities with our cases with respect to their neurodevelopmental and genital defects. Similar to our family, the most parsimonious mechanism is the missegregation of a balanced translocation ([Table 1](#OzanturkMCS000703TB1){ref-type="table"}; [Fig. 3](#OzanturkMCS000703F3){ref-type="fig"}; [@OzanturkMCS000703C14]).

DISCUSSION {#s3}
==========

Here, we have reported our genetic analyses of a nonconsanguineous Turkish pedigree with a constellation of structural anomalies affecting neurodevelopment, craniofacial and skeletal formation, and the genitourinary tract that do not conform readily to a recognized syndrome. Using a quad-based WES strategy combined with high-resolution SNP arrays, we found three candidate pathogenic drivers: a missense mutation on the X Chromosome and two CNVs arising from a likely balanced translocation in one of the parents. Functional testing of *CXorf36* revealed that the mutation is unlikely to be contributory, at least for the neurodevelopmental and craniofacial defects tested.

Retrospective review of cases with 5p deletions and 16q duplications that overlap the regions found in our patients suggest that each chromosomal aberration likely contributes to the complexity of the phenotype, with features such as the cat-like cry in one of our patients arising from the 5p deletion and hypotonia being shared as a consistent feature of the 16q duplication ([Fig. 3](#OzanturkMCS000703F3){ref-type="fig"}). At the same time, we note that neither 5p (del) nor 16q (dup) have been associated with genital hypoplasia. Although this might be a product of variable expressivity at either CNV, this is a feature shared between our patients and those reported to have both 5p and 16q dosage imbalances ([@OzanturkMCS000703C14]). The 16q duplication in both these studies is larger than what has been reported previously. Thus, one possibility is that the increased expression of transcripts in that interval drives this pathology. Alternatively, we speculate that genetic interactions between the two CNVs might be a driver of the structural malformations of the male gonads. Finally, given that our studies were focused primarily on the exome, we cannot exclude the possibility that additional pathogenic changes (SNV or CNV; regulatory or coding) elsewhere in the genome contribute to pathology, an increasingly reported phenomenon coincident with the expanded use of whole genome sequencing ([@OzanturkMCS000703C19]; [@OzanturkMCS000703C23]). The identification and careful phenotyping for each of these pathologies of additional patients harboring either or both CNVs as well as comprehensive whole-genome analysis of the individuals in this study will be necessary to resolve these possibilities.

We do not yet know which genes within these two CNVs contribute to each of the observed phenotypes; ultimately, the systematic dissection of CNVs will be required to identify phenotype drivers and potential epistatic effects resulting from genes affected by CNV(s) detected in humans ([@OzanturkMCS000703C13]; [@OzanturkMCS000703C9]). We anticipate that the unbiased dissection of large CNVs similar in size to those identified in this study will become possible with the increased throughput of genome-editing technologies ([@OzanturkMCS000703C15]) in model organisms.

METHODS {#s4}
=======

Ascertainment, WES, CoNIFER and XHMM Analysis, and Sanger Sequencing {#s4a}
--------------------------------------------------------------------

The parents and two affected siblings were sequenced using WES on an Illumina HiSeq platform using 100-bp paired-end reads at a median depth of \>80% at 20× as described previously ([@OzanturkMCS000703C3]). Briefly, DNA samples were fragmented and ligated with Illumina multiplex paired-end adapters. Adapter-ligated fragmented DNA was amplified using primers with sequencing barcodes. The precapture library was enriched by hybridizing to biotin-labeled VCRome 2.1 ([@OzanturkMCS000703C3]). Output data were mapped by Burrows--Wheeler aligner (BWA) ([@OzanturkMCS000703C21]). The variant calls were performed with Atlas-SNP and Atlas-indel as described previously ([@OzanturkMCS000703C7]). Data were filtered to retain functional variants (predicted to alter mRNA splicing or protein amino acid sequence) with an MAF of \<1% in the public 1000 Genomes SNP database, the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project, the Exome Variant Server (EVS; *n* = 6500 exomes), and the ARIC cohort (*n* = 2300 exomes). Finally, candidate variants were confirmed visually using the Integrative Genomics Viewer (IGV), followed by Sanger sequencing. Retained variants were placed into two categories: (1) primary candidates---variants that segregate perfectly with disease status, with coverage ≥5× and allele balance ≥20% in the proband; and (2) secondary candidates---inheritance is consistent with disease status (genotype of one parent may be missing; coverage may be \<5× in one of the parents; reduced quality \[e.g., more than two alleles at one site, one of which has \<20% of reads\]; coverage is ≥5× in the proband; see Supplemental Tables S1--S3 for details).

CNVs were identified using two programs: CoNIFER ([@OzanturkMCS000703C17]) and XHMM ([@OzanturkMCS000703C11]). Both programs were run with default parameters. To ensure highest sensitivity, we did not perform any filtering of the discovered CNVs. In addition to the four samples from the family, we included WES data from unrelated 200 in-house samples to enable better normalization of the depth of coverage. The discovered CNVs in each proband were annotated using a custom Perl script indicating the amount of overlap with known segmental duplications and known CNVs from the Database of Genomic Variants (DGV) as reported in the UCSC Genome Browser (<http://genome.ucsc.edu/cgi/hgGateway>).

High-Resolution Array {#s4b}
---------------------

Array analysis was carried out following the manufacturer\'s protocols on the high-resolution CytoScan HD array platform (Affymetrix), which contains more than 2.6 million markers, including 750,000 SNPs and 1.9 million nonpolymorphic probes. Data were analyzed with the Nexus software version 7.5 (BioDiscovery). We utilized the two major quality control metrics for Affymetrix array: (1) the median absolute pairwise difference (MAPD) score, which applies to copy-number probes, and (2) the SNP-quality control (QC), which applies to SNP probes. We mandated that the values for these parameters be ≤0.25 for MAPD and ≥0.15 for SNP-QC. We set cutoffs for our detection criteria for CNVs at 20 probes for both gains and losses, and the breakpoint positions of aberrant regions were converted to UCSC hg19 (UCSC Genome Browser, release February 2009).

Zebrafish Embryo Injection and Phenotyping {#s4c}
------------------------------------------

A splice-blocking MO targeting the exon 2--intron 2 boundary of *c9hxorf36* was designed and obtained from Gene Tools (5′-AAGCCACAAATTCAGACCTTCACCA-3′). The efficiency of the MO was confirmed by RT-PCR (reverse transcription--polymerase chain reaction). RNA was extracted from MO-injected embryos and controls at 3 dpf using TRIzol (Invitrogen). First-strand cDNA was synthesized using SuperScript III reverse transcriptase and random hexamers (Invitrogen), according to the manufacturer\'s instructions. We carried out PCR amplification using whole-embryo cDNA as template, and PCR products were subjected to direct DNA sequencing (Supplemental Fig. S2). One nanoliter of diluted MO (3, 6, and 9 ng) was injected into zebrafish embryos at the one- to four-cell stage. Injected embryos were fixed in 4% PFA (paraformaldehyde) overnight at 5.5 dpf (Alcian blue staining) and at 2 dpf for phospho-histone H3 staining. Alcian blue staining was performed to demarcate cartilage structures as described previously ([@OzanturkMCS000703C8]). Phospho-histone H3 immunostaining was performed as described previously ([@OzanturkMCS000703C13]) using anti-histone H3 (ser10)-R, (sc-8656-R, Santa Cruz; 1:500 dilution). Embryos were imaged on a Nikon AZ100 microscope facilitated by NIS Elements software.
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